# RNN 2nd Gen Model Zoetis Inc. Pharmaceutical preparations

Prediction models:
Subscribe >> Deal exit on
Feb. 21, 2020
Deal entry on
Feb. 21, 2020
17.01%Expected margin
68.85% successful of 61 deals
$ 142.23 Last close price
at 21-feb-2020

ZTS

Model's trade recommendations No return for period yet

2.40% Annual return

$38.77B Market Cap

β 0.97  

ZTS

Model (following trade recommendations)

ZTS

Underlying stock

S&P 500

Index
Return for period
4.34%
1.78%
52wk return
50.33%
16.82%
52wk Range
92.41—144.94
2000.54—2399.63
Sortino ratio 0.38
Sharpe ratio 0.28
Norm. RMSE 15.77%
Downside risk 6.26%
Volatility 0.00%
  • 0.50 (0.63%) Div (Yield)
  • BUY Analysts consensus recommendation

Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Zoetis Inc. (ZTS) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for ZTS model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a regular basis.

Float 484M
P/E 30.50
Shares Outstanding 485M
% Held by Insiders 0.35%
% Held by Institutions 92.60%
EPS (last reported FY) $2.40
EPS (last reported Q) $0.75
EPS, estimated (last reported Q) $0.70
Total revenues $5 B
Net income $1 B